Nuvation Bio (NUVB) Expected to Announce Earnings on Wednesday

Nuvation Bio (NYSE:NUVB - Get Free Report) will likely be releasing its Q1 2025 earnings data after the market closes on Wednesday, May 7th. Analysts expect the company to announce earnings of ($0.16) per share and revenue of $0.42 million for the quarter.

Nuvation Bio Stock Down 1.0 %

NYSE NUVB traded down $0.03 during trading on Monday, reaching $2.44. 1,787,370 shares of the stock traded hands, compared to its average volume of 2,140,168. Nuvation Bio has a fifty-two week low of $1.54 and a fifty-two week high of $3.97. The firm has a market cap of $824.68 million, a price-to-earnings ratio of -1.12 and a beta of 1.42. The stock's 50-day moving average price is $1.96 and its 200 day moving average price is $2.37.

Insider Buying and Selling

In other news, CEO David Hung purchased 200,000 shares of Nuvation Bio stock in a transaction on Friday, April 4th. The stock was purchased at an average price of $1.66 per share, with a total value of $332,000.00. Following the transaction, the chief executive officer now directly owns 58,481,054 shares in the company, valued at $97,078,549.64. The trade was a 0.34 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link. 29.93% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on NUVB shares. Citizens Jmp assumed coverage on shares of Nuvation Bio in a report on Wednesday, April 23rd. They issued a "mkt outperform" rating and a $6.00 price target for the company. Jones Trading assumed coverage on Nuvation Bio in a research note on Wednesday, March 12th. They issued a "buy" rating and a $10.00 target price for the company. Royal Bank of Canada reaffirmed an "outperform" rating and set a $10.00 price target (up previously from $6.00) on shares of Nuvation Bio in a research report on Tuesday, January 7th. JMP Securities began coverage on Nuvation Bio in a research report on Wednesday, April 23rd. They issued a "market outperform" rating and a $6.00 price objective for the company. Finally, HC Wainwright dropped their target price on shares of Nuvation Bio from $11.00 to $10.00 and set a "buy" rating on the stock in a report on Monday, March 10th. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $7.83.

About Nuvation Bio

Nuvation Bio Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer.